| Authors: |
Titulaer J; Section of Neuropharmacology and Addiction Research, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden; Section of Neuropsychopharmacology, Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden., Gottfridsson R; Section of Neuropharmacology and Addiction Research, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden., Nordling D; Section of Neuropharmacology and Addiction Research, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden; Division of Psychiatry, Clinical Sciences Helsingborg, Lund University, Lund, Sweden., Fagerström E; Section of Neuropharmacology and Addiction Research, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden., Eberhard J; Division of Psychiatry, Clinical Sciences Helsingborg, Lund University, Lund, Sweden., Konradsson-Geuken Å; Section of Neuropharmacology and Addiction Research, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden; Section of Neuropsychopharmacology, Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden; Division of Psychiatry, Clinical Sciences Helsingborg, Lund University, Lund, Sweden. Electronic address: Asa.konradsson-geuken@farmbio.uu.se. |